Es idéntico el nivel de survivina entre los adenomas de colon proximal y distal?

Autores/as

DOI:

https://doi.org/10.31051/1852.8023.v14.n2.37625

Palabras clave:

colon proximal y distal, adenomas, survivin

Resumen

Objetivos: Se conocen diferencias considerables entre el colon proximal y el distal, estas incluyen características embriológicas, anatómicas, histológicas, bioquímicas y fisiológicas. Las distinciones antes mencionadas pueden influir en el desarrollo de entidades clínico-morfológicas variables. La proteína antiapoptótica multifuncional survivina participa en la regulación del ciclo celular, las cascadas apoptóticas y estimula la angiogénesis. Material y métodos: Se evaluó inmunohistoquímicamente el patrón de expresión de la proteína antiapoptótica survivina en un panel de 243 adenomas de colon para determinar su asociación con la localización colónica. En cada sección se evaluó la compartimentación subcelular de la survivina y la intensidad de la inmunorreacción. Resultados: La survivina se expresó en 190 casos (78,2%). El análisis estadístico confirmó una correlación significativa de la compartimentación subcelular de survivina y la intensidad de la inmunorreacción con la localización de los adenomas en el colon. Conclusiones: Teniendo en cuenta las características únicas de la survivina, su patrón de expresión en los adenomas del lado proximal y las distinciones entre el colon derecho e izquierdo, suponemos que el nivel de survivina puede contribuir a un mayor fenotipo proliferativo de los adenomas proximales.

Citas

Adamkov M, Výbohová D, Tupá V, Chylíková J, Horáček J, Benčat M. 2015. Expression and significance of survivin in colorectal high grade and low grade adenomas. Acta Histochemica 117: 590-4. doi: 10.1016/j.acthis.2015.05.006.

Adamkov M, Výbohová D, Drahošová S, Galbavý Š. 2018. Mismatch repair proteins and survivin in adenomatous colon polyps with low grade and high grade dysplasia: an immunohistochemical study. Rev Arg de Anat Clin 10(3): 98-111. https://doi.org/10.31051/1852.8023.v10.n3.20923.

Baran B, Ozupek NM, Tetik NY, Acar E, Bekcioglu O, Baskin Y. 2018. Difference between left-sided and right-sided colorectal cancer: A focused review of literature. Gastroenterol Res 11(4): 264-73. doi: https://doi.org/10.14740/gr1062w.

Benedix F, Kube R., Meyer F, Schmidt U, Gastinger I, Lippert H. 2010. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 53(1): 57-64. doi: 10.1007/DCR.0b013e3181c703a4.

Brennan DJ, Rexhepaj E, O´Brien SL, McSherry E, O´Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM. 2008. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14(9): 2681-9. doi:10.1158/1078-0432.CCR-07-1760.

Bustamante-Lopez LA, Nahas SC, Nahas CSR, Pinto RA, Marques CFS, Cecconello I. 2019. Is there a difference between right- versus left- sided colon cancers? Does side make any difference in long-term follow-up? ABCD Arq Bras Cir Dig 32(4): e1479. doi: 10.1590/0102-672020190001e1479.

Clevers H. 2006. Wnt/beta-catenin signaling in development and disease. Cell 127(3): 469-80.

Gil-Kulik P, Krzyźanowski A, Dudzińska E, Karwat J, Chomik P, Świstowska M, Kondracka A, Kwaśniewska A, Cioch M, Jojczuk M, Nogalski A, Kocki J. 2019. Potential involvement of BIRC5 in maintaining pluripotency and cell differentiation of human stem cells. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2019/8727925.

Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. 2011. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer 10(3): 188-93. doi: 10.1016/j.clcc.2011.03.014.

Chen X, Duan N, Zhang C, Zhang W. 2016. Survivin and tumorigenesis: Molecular mechanisms and therapeutic strategies. J Cancer 7(3): 314-23. doi: 10.7150/jca.13332.

Chen Y, Bieerkehazhi S, Li X, Ma L, Yibulayin W, Ran J. 2021. Survivin regulates bad gene expression by binding to its promoter and modulates cell cycle and apoptosis in esophageal carcinoma cell. J Oncol. https://doi.org/10.1155/2021/1384289.

Cheng X, Xu X, Chen D, Zhao F, Wang W. 2019. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer. Biomed Pharmacother 110: 473-81. https://doi.org/10.1016/j.bopha.2018.11.082.

Jaiswal PK, Goel A, Mittal RD. 2015. Survivin: A molecular biomarker in cancer. Indian J Med Res 141: 389-97.

Jakubowska K, Pryczynicz A, Dymicka-Piekarska V, Famulski W, Guzińska-Ustymowicz K. 2016. Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients. Oncology Letters 12: 3591-7. doi: 10.3892/ol.2016.5075.

Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC. 2011. Impacting tumor cell-fate by targetingtheinhibitor of apoptosisproteinsurvivin. MolecularCancer 10: 35. doi:10.1186/1476-4598-10-35.

Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. 2003. Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-9. doi: 10.1016/S0140-6736(03)13910-4.

Kováčová Z, Hodorová I. 2021. Carbonic Anhydrase IX and Survivin in Colorectal Adenocarcinoma Cells: Slovakian Population Study. Biology 10: 872. https://doi.org/10.3390/biology10090872

Li F. 2005. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92:212-6.doi: 10.1038/sj.bjc.6602340.

Li F, Brattain MG. 2006. Role of the survivin gene in pathobiology. Am J Pathol 169: 1-11. doi: 10.2353/ajpath.2006.060121.

Li F, Aljahdali I, Ling X. 2019. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J Exp Clin Cancer Res 38: 368. https://doi.org/10.1186/s13046-019-1362-1.

Lim DR, Kuk JK, Kim T, Shin EJ. 2017. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? Medicine (Baltimore) 96(42):e8241. Doi: 10.1097/MD.0000000000008241.

Lucchesi CA, Zhang J, Ma B, Nussinov R, Chen X. 2021. Survivin expression is differentially regulated by a selective crosstalk between Rbm38 and miRNAs let-7b or miR-203a. Cancer Res. doi: 10.1158/0008-5472.CAN-20-3157.

Missiaglia E, Jacobs B, D´Ario G, Di Narzo AF, Soneson C, Budinska E,Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S. 2014. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25:1995-2001. doi:10.1093/annonc/mdu275.

Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Reid JG, Santibanez J, Shinbrot E, Trevino LR, Wu YQ, Wang M, Gunaratne P, Donehower LA, Creighton CJ, Wheeler DA, Gibbs RA et al. The Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. 2012. Nature 487(7407): 330-7. https://doi.org/10.1038/nature11252

Pohl H, Robertson DJ, Mott LA, Ahnen DJ, Burke CA, Barry EL,Bresalier RS, Figueiredo JC, Shaukat A, Sandler RS, Baron JA. 2016. Association between adenoma location and risk of recurrence. GastrointestEndosc 84(4):709-16. doi:10.1016/j.gie.2016.02.048.

Shao Q, Xu J, Deng R, Wei W, Zhou B, Yue Ch, Zhu M, Zhu H. 2018. The expressions of YAP1, β-catenin and survivin in colon cancer tissues and their clinical significance. Int J Clin Exp Pathol 11(12): 6032-8.

Silke J, Vucic D. 2014. IAP family of cell death and signaling regulators. Methods Enzymol 545: 35-65. doi: 10.1016/B978-0-12-801430-1.00002-0.

Wang H, Jin S, Lu H, Mi S, Shao W, Zuo X, Yin H, Zeng S, Shimamoto F, Qi G. 2017. Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics. Oncology Letters 14: 1011-6. https://doi.org/10.3892/ol.2017.6218.

Warrier NM, Agarwal P, Kumar P. 2020. Emerging importance of survivin in stem cells and cancer: the development of new cancer therapeutics. Stem Cell Rev Rep 16(5): 828-52. doi:10.1007/s12015-020-09995-4.

Weiss JM, Pfau PR, O´Connor ES, King J, LoConte N, Kennedy G, Smith MA. 2011. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results Medicare data. J Clin Oncol 29(33): 4401-9. doi: 10.1200/JCO.2011.36.4414.

Wheatley SP, Altieri DC. 2019. Survivin at a glance. J Cell Science 132. doi:10.1242/jcs.223826.

Zhou J, Guo X, Chen W, Wang L, Jin Y. 2020. Targeting survivin sensitizes cervical cancer cells to radiation treatment. Bioengineered 11(1):130-40. doi: 10.1080/21655979.2020.1717297.

Yang D, Welm A, Bishop JM. 2004. Celldivision and cellsurvival in theabsence of survivin. ProcNatlAcadSci U S A 101: 15100-5.

Yang DD, Wu XL, HE K, Jia GH, Wang LK. 2013. Expression and clinical significance of survivin in colorectal cancer, adenoma and normal colorectal tissues. Mil Med Sci 7: 525-528,534.

Yong-Gang L, Fang Y, Qing Y, Jiang-Hao Ch, Ling W. 2010. The role of survivin in diagnosis, prognosis and treatment of breastcancer. J ThoracDis 2: 100-10. DOI: 10.3978/j.issn.2072-1439.2010.02.02.009

Descargas

Publicado

2022-07-29

Cómo citar

Adamkov, M., Hurta Csizmar, S., Mestanova, V., Vybohova, D., & Krajnakova, B. (2022). Es idéntico el nivel de survivina entre los adenomas de colon proximal y distal?. Revista Argentina De Anatomía Clínica, 14(2), 58–64. https://doi.org/10.31051/1852.8023.v14.n2.37625

Número

Sección

Contribuciones Originales